225 related articles for article (PubMed ID: 29577765)
1. Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection.
Ottman AA; Townsend ML; Hashem MG; DiMondi VP; Britt RB
Ann Pharmacother; 2018 Aug; 52(8):763-768. PubMed ID: 29577765
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a specialty hepatitis C virus telephone pharmacy service.
Sabourin AA; Fisher-Grant KK; Saulles AR; Mohammad RA
Am J Health Syst Pharm; 2021 May; 78(Supplement_2):S38-S45. PubMed ID: 33684928
[TBL] [Abstract][Full Text] [Related]
3. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
[TBL] [Abstract][Full Text] [Related]
4. Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
Ottman AA; Townsend ML; Hashem MG; Britt RB
Ann Pharmacother; 2019 Jun; 53(6):581-587. PubMed ID: 30654625
[TBL] [Abstract][Full Text] [Related]
5. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.
Langness JA; Nguyen M; Wieland A; Everson GT; Kiser JJ
World J Gastroenterol; 2017 Mar; 23(9):1618-1626. PubMed ID: 28321163
[TBL] [Abstract][Full Text] [Related]
6. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
Kondili LA; Gaeta GB; Ieluzzi D; Zignego AL; Monti M; Gori A; Soria A; Raimondo G; Filomia R; Di Leo A; Iannone A; Massari M; Corsini R; Gulminetti R; Gatti Comini A; Toniutto P; Dissegna D; Russo FP; Zanetto A; Rumi MG; Brancaccio G; Danieli E; Brunetto MR; Weimer LE; Quaranta MG; Vella S; Puoti M
PLoS One; 2017; 12(2):e0172159. PubMed ID: 28245248
[TBL] [Abstract][Full Text] [Related]
7. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project.
Chamorro-de-Vega E; Rodriguez-Gonzalez CG; Gimenez-Manzorro A; de Lorenzo-Pinto A; Iglesias-Peinado I; Herranz A; Sanjurjo M;
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28836363
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.
Maasoumy B; Port K; Calle Serrano B; Markova AA; Sollik L; Manns MP; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1365-72. PubMed ID: 24127648
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
González-Colominas E; Broquetas T; Retamero A; García-Retortillo M; Cañete N; Coll S; Pellicer R; Giménez MD; Cabrero B; Bory F; Knobel H; Salas E; Solà R; Carrión JA
Liver Int; 2015 May; 35(5):1557-65. PubMed ID: 25385188
[TBL] [Abstract][Full Text] [Related]
11. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
Hui VW; Au CL; Lam ASM; Yip TC; Tse YK; Lai JC; Chan HL; Wong VW; Wong GL
Hepatol Int; 2022 Dec; 16(6):1318-1329. PubMed ID: 36074319
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Direct-Acting Antiviral Treatment Selection, Treatment Failure, and Use of Drug-Drug Interactions in a State Medicaid Program.
Keast SL; Holderread B; Cothran T; Skrepnek GH
J Manag Care Spec Pharm; 2019 Nov; 25(11):1261-1267. PubMed ID: 31663456
[TBL] [Abstract][Full Text] [Related]
14. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.
Vermehren J; Peiffer KH; Welsch C; Grammatikos G; Welker MW; Weiler N; Zeuzem S; Welzel TM; Sarrazin C
Aliment Pharmacol Ther; 2016 Oct; 44(8):856-65. PubMed ID: 27549000
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.
Murray M
Clin Pharmacokinet; 2023 Oct; 62(10):1365-1392. PubMed ID: 37731164
[TBL] [Abstract][Full Text] [Related]
17. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
Rodríguez-Torres M
Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center.
Yang S; Britt RB; Hashem MG; Brown JN
J Manag Care Spec Pharm; 2017 Mar; 23(3):364-369. PubMed ID: 28230455
[TBL] [Abstract][Full Text] [Related]
19. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of direct-acting antivirals in hepatitis C infected patients with mental disorders: Results in real clinical practice.
Margusino-Framiñán L; Bobadilla-Pérez E; Cid-Silva P; Rodríguez-Sotelo A; Yáñez-Rubal JC; Mena-de-Cea Á; Suárez-López F; Prieto-Pérez A; Giménez-Arufe V; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
J Med Virol; 2020 Dec; 92(12):3488-3498. PubMed ID: 32181917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
